Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06977880
PHASE1

A Phase 1, First-in-human Study of MORF-440 (LY4292009) in Healthy Participants

Sponsor: Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the safety and tolerability of single ascending doses of MORF-440 administered to healthy participants single-ascending dose (SAD) and maximum ascending dose (MAD) substudy.

Official title: A Phase 1, First-in-human Study of MORF-440 in Healthy Participants, Including Single and Multiple Ascending Dose Cohorts

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

80

Start Date

2025-02-19

Completion Date

2026-03

Last Updated

2026-01-20

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

LY4292009

Administered orally

DRUG

Placebo

Administered orally.

Locations (1)

Altasciences Company Inc.

Mount Royal, Canada